MPX Bioceutical Corp. (MPXEF)

[kb406]

The TSX threat should has no material impact on CBICF/BCC, as it is listed on the CNSX and not the TSX or TSXV. The CNSX follows the CSE guidance, which was (Aug 4, 2017):

There are particular risks related to the conflicting U.S. federal and state laws surrounding both medical and recreational use of cannabis. CSE maintains the position that appropriate risk disclosure for existing and potential investors should include a comprehensive discussion of the current legal framework, including the federal law and current enforcement initiatives, as well as the state and municipal laws pursuant to which an issuer will conduct its business.

So, as long as BCC continues to make "appropriate risk disclosure," then it should be fine with respect to maintaining its listed status.

Now, this doesn't mean that that TSX turmoil can't impact the company's stock price. The entire sector seems to drop after these TSX scares, even if the company has no business assets in the US or is not listed on the TSX/TSXV.

Finally, its worth acknowledging that the TSX issues do impact CBICF/BCC in that they will not be able to uplist under the current TSX rules. That limits institutional investment in the near term, until either TSX changes their stance or the US legalizes.